Xeris Biopharma (NASDAQ:XERS) Insider Sells $173,385.32 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider John Patrick Shannon, Jr. sold 23,242 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $7.46, for a total value of $173,385.32. Following the completion of the sale, the insider owned 2,643,153 shares in the company, valued at approximately $19,717,921.38. This represents a 0.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Xeris Biopharma Stock Up 1.1%

XERS stock traded up $0.08 during trading on Monday, reaching $7.26. 2,629,742 shares of the company’s stock were exchanged, compared to its average volume of 2,529,156. Xeris Biopharma Holdings, Inc. has a 1-year low of $2.82 and a 1-year high of $10.08. The firm has a market cap of $1.20 billion, a PE ratio of -72.59 and a beta of 0.21. The company’s fifty day moving average price is $8.35 and its 200-day moving average price is $6.51.

Institutional Trading of Xeris Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cetera Investment Advisers raised its stake in Xeris Biopharma by 3.9% during the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after purchasing an additional 1,735 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Xeris Biopharma by 7.6% during the second quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company’s stock valued at $150,000 after buying an additional 2,264 shares in the last quarter. R Squared Ltd raised its position in Xeris Biopharma by 27.7% during the first quarter. R Squared Ltd now owns 15,730 shares of the company’s stock valued at $86,000 after buying an additional 3,410 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Xeris Biopharma by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 54,472 shares of the company’s stock worth $254,000 after acquiring an additional 3,562 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after acquiring an additional 3,594 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on XERS shares. Zacks Research lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, October 8th. Oppenheimer reissued an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Finally, Piper Sandler increased their price target on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.58.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.